"Designing Growth Strategies is in our DNA"

Neurodegenerative Diseases Drugs Market Size, Share and Industry Analysis By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others), By Route of Administration (Oral, Injection, Transdermal, Others), By End User and Regional Forecast 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI100661

 


To get information on various segments, share your queries with us

ATTRIBUTE

 DETAILS

Segmentation

By Drug Class

  • Immunomodulator 
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Others

By Disease Indication

  • Multiple Sclerosis
  • Parkinson’s Disease
  • Alzheimer's Disease
  • Spinal Muscular Atrophy (SMA)
  • Others

By Route of Administration

  • Oral
  • Injection
  • Transdermal

By End User

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
  • 2019-2032
  • 2024
  • 2019-2023
  • 166
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann